Phase 2 CUBICIN study for prosthetic joint infections meets primary endpoint

Links shared publicly online about this topic.

1,011
total visits

Phase 2 CUBICIN study for prosthetic joint infections meets primary endpoint

Cubist Pharmaceuticals, Inc., a leading acute care therapeutics company, today announced that its Phase 2 safety study of CUBICIN (daptomycin for injection) in the treatment of prosthetic joint infections caused by certain Gram positive pathogens met its study objectives. This study was a first-of-its-kind randomized controlled Phase 2 trial studying anti-infective therapy in the setting of 2-stage surgery for the replacement of infected prosthetic hip or knee joints.

View full resource at news-medical.net

Tags: Infection, Knee Pain, Joint, Pharma, Phase 2 Clinical Trial, Surgery